| 1584 |
National Cancer Institute |
Html |
en |
Anal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of anal cancer. |
| cancer treatment | 0.433322 |
| diagnose anal cancer | 0.423593 |
| Anal Cancer Treatment | 0.419952 |
| metastatic anal cancer | 0.412176 |
| Frequent anal redness | 0.384126 |
| body | 0.434753 |
| PDQ cancer information | 0.446236 |
| clinical trial search | 0.504831 |
| anal cancer spreads | 0.410812 |
| clinical trials | 0.887836 |
| cancer information summary | 0.419039 |
| clinical trial | 0.647154 |
| anus | 0.449257 |
| patients | 0.429875 |
| treatment clinical trial | 0.380816 |
| NCI PDQ cancer | 0.384659 |
| malignant tumor cells | 0.380765 |
| radiation therapy | 0.718553 |
| Treatment Editorial Board | 0.382929 |
| human immunodeficiency virus | 0.375987 |
| rectum | 0.3805 |
| General information | 0.426863 |
| general cancer information | 0.376766 |
| treatment | 0.612453 |
| abdominoperineal resection | 0.403255 |
|
| receptive anal intercourse | 0.384527 |
| new cancer treatments | 0.377037 |
| NCI-supported cancer | 0.425485 |
| cancer cells | 0.46124 |
| Cancer Information Service | 0.376813 |
| sphincter muscles | 0.384557 |
| treatment clinical trials | 0.40741 |
| National Cancer Institute | 0.461854 |
| Recurrent anal cancer | 0.435676 |
| new treatment | 0.505194 |
| external-beam radiation therapy | 0.454262 |
| IIIA anal cancer | 0.402258 |
| IIIB anal cancer | 0.401297 |
| anal cancer | 0.792189 |
| new treatment options | 0.426789 |
| anal opening | 0.376839 |
| cancer clinical trials | 0.506964 |
| stage | 0.400723 |
| Local resection | 0.453758 |
| tumor | 0.401265 |
| comprehensive cancer information | 0.375327 |
| internal radiation therapy | 0.496063 |
| cancer | 0.970468 |
| information | 0.453326 |
|
CLICK HERE |
| 1789 |
National Cancer Institute |
Html |
es |
Complicaciones gastrointestinales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del estreñimiento, impacción, obstrucción intestinal y diarrea como complicaciones del cáncer o su tratamiento. Se discute el manejo de estos problemas. |
| PDQ Complicaciones | 0.530388 |
| pelvis causa inflamación | 0.572317 |
| siguientes procedimientos | 0.608568 |
| hormona tiroidea | 0.545669 |
| siguientes aspectos | 0.533891 |
| Lactobacillus acidophilus | 0.526037 |
| rayos x | 0.532507 |
| media hora | 0.541392 |
| diarrea aguda | 0.693188 |
| largo plazo | 0.569789 |
| siguientes preguntas | 0.540731 |
| Busque privacidad | 0.543195 |
| productos lácteos | 0.560479 |
| medicamentos iv | 0.544267 |
| siguientes indicaciones | 0.527177 |
| tratamiento quizás | 0.572007 |
| vÃa iv | 0.522455 |
| cáncer.ampliar colonoscopia | 0.551466 |
| Instituto Nacional | 0.536707 |
| Coma porciones | 0.524947 |
| heces retenidas | 0.545367 |
| intestino.ampliar procedimiento | 0.541183 |
| suficiente ejercicio | 0.545879 |
| crónica.Obstrucción intestinal aguda | 0.64888 |
|
| pacientes quizás | 0.581825 |
| sÃntomas quizás | 0.540102 |
| metabolismo corporal concentración | 0.581977 |
| cantidades correctas | 0.533739 |
| régimen brat | 0.52571 |
| ¿El estreñimiento | 0.640368 |
| medicamentos opioides | 0.717569 |
| ejercicio lesión | 0.545303 |
| gráfico muestra afecciones | 0.567465 |
| National Cancer Institute | 0.520678 |
| La nutrición | 0.589361 |
| alto contenido | 0.5222 |
| siguientes signos | 0.535436 |
| Physician Data Query | 0.576854 |
| enzimas pancreáticas | 0.556797 |
| radiación aguda | 0.557929 |
| cuerpo).ampliar anatomÃa | 0.552347 |
| RadiografÃa abdominal | 0.535361 |
| suficiente cantidad | 0.531328 |
| enteritis aguda | 0.993176 |
| siguientes complicaciones | 0.586671 |
| obstrucción intestinal aguda | 0.803119 |
| cirugÃa.Algunos medicamentos | 0.559484 |
| siguientes pruebas | 0.618199 |
|
CLICK HERE |
| 1851 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de tiroides (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides. |
| siguientes procedimientos | 0.422153 |
| hormona tiroidea | 0.492622 |
| bLos ganglios | 0.448367 |
| Hürthle cell carcinoma | 0.418971 |
| mÃnima diseminación | 0.464789 |
| T4b Enfermedad | 0.438377 |
| American Cancer Society | 0.43686 |
| European Thyroid Association | 0.427771 |
| thyroid disease | 0.486942 |
| niveles i | 0.45199 |
| Thyroid Association | 0.441602 |
| fase iii | 0.434728 |
| Natl Cancer Inst | 0.440945 |
| Thyroid calcification | 0.433055 |
| thyroid with | 0.432277 |
| Prognostic factors | 0.431082 |
| ≤2 cm | 0.731745 |
| patients with | 0.416562 |
| tiroides estadio | 0.461688 |
| N1a Metástasis | 0.590742 |
| N1b Metástasis | 0.55338 |
| American Thyroid Association | 0.427447 |
| papillary thyroid carcinoma | 0.534329 |
| tejidos blandos peritiroideos | 0.507165 |
| glándula tiroides | 0.891491 |
|
| tumores papilares | 0.421501 |
| nivel vii | 0.450974 |
| Lennard CM | 0.428158 |
| tiroides tipo | 0.453807 |
| ablación tiroidea | 0.436707 |
| French Thyroid Cancer | 0.436044 |
| M0 T1 | 0.439686 |
| thyroid cancer | 0.993324 |
| cápsula tiroidea | 0.541937 |
| thyroid carcinoma with | 0.448553 |
| tejidos blandos subcutáneos | 0.474653 |
| differentiated carcinoma | 0.433423 |
| follicular thyroid carcinomas | 0.439446 |
| thyroid carcinoma depends | 0.445887 |
| thyroid carcinomas | 0.753573 |
| Surg Oncol | 0.439117 |
| pronóstico adverso | 0.424396 |
| cartÃlagos tiroides | 0.469208 |
| Thyroid tumors | 0.433 |
| estadios tnm | 0.421127 |
| American Joint Committee | 0.423622 |
| ganglios linfáticos retrofarÃngeos | 0.70543 |
| lobectomÃa tiroidea | 0.423995 |
| AJCC Cancer Staging | 0.417512 |
|
CLICK HERE |
| 1909 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica. |
| siguientes procedimientos | 0.425256 |
| células madre | 0.845072 |
| Chronic Myelogenous Leukemia | 0.438357 |
| leucemia linfoblástica aguda | 0.438362 |
| hueso compacto | 0.417479 |
| enlace drugs approved | 0.436902 |
| cromosoma filadelfia | 0.526385 |
| célula madre mieloide | 0.437781 |
| Sudores nocturnos | 0.404959 |
| células anormales.ampliar aspiración | 0.417986 |
| enlace medicamentos | 0.404489 |
| National Cancer Institute | 0.403419 |
| siguientes riesgos | 0.40277 |
|
| Instituto Nacional | 0.405884 |
| célula madre linfoide | 0.438967 |
| PDQ Tratamiento | 0.410126 |
| hijos.ampliar cromosoma filadelfia | 0.412419 |
| leucemia mielógena | 0.99599 |
| Physician Data Query | 0.412686 |
| laboratorio piezas | 0.403757 |
| leucemia mieloide aguda | 0.437955 |
| siguientes exámenes | 0.405471 |
| célula madre | 0.512002 |
| células sanguÃneas maduras | 0.448469 |
| ósea elabora células | 0.429135 |
| siguientes sumarios | 0.40998 |
|
CLICK HERE |
| 2011 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón. |
| lung cancer screening | 0.491865 |
| Berg CD | 0.308884 |
| UK Lung Cancer | 0.309828 |
| Cooperative Early Lung | 0.306877 |
| Lung Cancer Study | 0.310626 |
| lung cancer | 0.996403 |
| Reduced lung-cancer mortality | 0.308509 |
| American Cancer Society | 0.314872 |
| Sloan-Kettering Lung Study | 0.306329 |
| Extended lung | 0.305748 |
| lung-cancer screening | 0.305282 |
| Lung Screening Trial | 0.34779 |
| Preventive Services Task | 0.315666 |
| early lung cancer | 0.370281 |
| Cancer Res | 0.308506 |
| screening results | 0.305543 |
| exámenes detección | 0.3124 |
| Screening Trial | 0.41076 |
| lung-cancer mortality with | 0.308638 |
| Randomized Danish Lung | 0.306065 |
| CT screening | 0.322848 |
| Natl Cancer Inst | 0.348878 |
| small lung | 0.309116 |
| Lung Cancer Risk | 0.310447 |
| from baseline screening | 0.305357 |
|
| More lung | 0.305626 |
| Screening Trial with | 0.311542 |
| early stage lung | 0.306471 |
| Is curable lung | 0.306471 |
| cytologic screening | 0.312546 |
| Hocking WG | 0.305973 |
| Hopkins Lung Project | 0.306129 |
| CT screening according | 0.305575 |
| Danish Lung Cancer | 0.338861 |
| Lung Cancer Action | 0.32014 |
| randomised danish lung | 0.306155 |
| National Lung Screening | 0.345051 |
| Intern Med | 0.314222 |
| lung cancer detection | 0.362796 |
| Services Task Force | 0.31539 |
| Randomized Lung Cancer | 0.310797 |
| from semi-annual screening | 0.30542 |
| PLCO Cancer Screening | 0.310194 |
| Mayo Lung Project | 0.341943 |
| lung cancers detected | 0.306094 |
| Memorial Sloan-Kettering | 0.306282 |
| Cancer Action Project | 0.310925 |
| Lung Project revisited | 0.306785 |
| Cancer Screening Trial | 0.390805 |
|
CLICK HERE |
| 2026 |
National Cancer Institute |
Html |
es |
Prevención del cáncer colorrectal (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer colorrectal y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| colorectal adenoma chemoprevention | 0.338068 |
| colorectal neoplasia among | 0.319011 |
| long-term risk | 0.313313 |
| Adults With Colorectal | 0.319346 |
| Sin embargo | 0.339382 |
| Gastrointest Endosc | 0.311269 |
| largo plazo | 0.32477 |
| CPS II | 0.314437 |
| flexible sigmoidoscopy screening | 0.31731 |
| Preventive Services Task | 0.332229 |
| colorectal cancer | 0.908646 |
| population-based study | 0.314294 |
| Estados Unidos | 0.331084 |
| Natl Cancer Inst | 0.334301 |
| Women's Health Study | 0.324602 |
| after colonoscopy | 0.309105 |
| CCR multivariantes | 0.345859 |
| Aspirin Trial | 0.311104 |
| Women's Health Initiative | 0.338408 |
| colorectal adenomatous polyps | 0.317676 |
| Health Initiative | 0.348288 |
| colorrectal hereditario | 0.317986 |
| Women's Health | 0.346194 |
| cancer prevention | 0.326424 |
| Rothwell PM | 0.314674 |
|
| colorectal adenoma | 0.357654 |
| Health Study | 0.364941 |
| sporadic colorectal adenomas | 0.324242 |
| RR multivariante | 0.309686 |
| CCR clÃnico | 0.37477 |
| Health Study Research | 0.310687 |
| left-sided colorectal neoplasms | 0.31858 |
| primary prevention | 0.311318 |
| Hereditary Cancer Syndromes | 0.314398 |
| Epidemiol Biomarkers Prev | 0.320559 |
| arteriopatÃa coronaria | 0.30952 |
| riesgo promedio | 0.330242 |
| antecedentes familiares | 0.330027 |
| Cancer Prevention Study | 0.318847 |
| Intern Med | 0.471733 |
| cohort study using | 0.309014 |
| Clin Oncol | 0.310431 |
| Services Task Force | 0.331368 |
| systematic review | 0.369209 |
| Giovannucci E | 0.31569 |
| physical activity | 0.319835 |
| Protection from | 0.309663 |
| Women’s Health Initiative | 0.324227 |
| with colorectal cancer | 0.348991 |
|
CLICK HERE |
| 15777 |
National Cancer Institute |
Html |
en |
Research Directions for Childhood Cancer |
NCI has identified areas for which more research is needed on childhood cancers, including investments in basic research, immunotherapies, and moleculary targeted therapies. |
| small molecule inhibitors | 0.412891 |
| childhood cancers | 0.94672 |
| critical gaps | 0.332101 |
| major treatment advance | 0.412137 |
| Pediatric MATCH | 0.392576 |
| research proposals | 0.436951 |
| peer review process | 0.389826 |
| immunotherapy technique | 0.352473 |
| NCI scientists Lawrence | 0.622389 |
| chimeric antigen receptor | 0.460833 |
| cancer cells | 0.401044 |
| highly trained scientists | 0.390662 |
| high-priority goal | 0.343491 |
| cancer research | 0.527941 |
| best scientific proposals | 0.421088 |
| pediatric patients | 0.416725 |
| pediatric cancer | 0.412777 |
| research areas | 0.34678 |
| T-cell receptor | 0.362608 |
| specific disease area | 0.405285 |
| clinical trials | 0.669991 |
| immunotherapy treatments | 0.349585 |
| NCI leadership | 0.495193 |
| Tumor DNA sequencing | 0.405564 |
|
| Pediatric Brain Tumor | 0.687267 |
| NCI-COG Pediatric Molecular | 0.487101 |
| NCI-sponsored clinical trials | 0.416329 |
| cancer immunology | 0.348212 |
| research funding decisions | 0.424865 |
| NCI funding opportunities | 0.589573 |
| rigorous grant application | 0.388949 |
| NCI portfolio | 0.493947 |
| rapidly advancing field | 0.423802 |
| new approaches | 0.32698 |
| advanced cancers | 0.402816 |
| research topic | 0.333717 |
| Pediatric Oncology Branch | 0.692641 |
| young adult patients | 0.616776 |
| NCI | 0.771754 |
| Children’s Oncology | 0.432835 |
| research category | 0.33728 |
| Brain Tumor Consortium | 0.615122 |
| Oncology Group | 0.433591 |
| NCI’s Steven | 0.52013 |
| past decade | 0.330224 |
| NCI Center | 0.621549 |
| adoptive cell transfer | 0.42055 |
|
CLICK HERE |
| 16145 |
National Cancer Institute |
Html |
es |
Virus de la enfermedad de Newcastle (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer. |
| células anfitrionas | 0.602816 |
| Centro Nacional | 0.427496 |
| inmunitario fabrique anticuerpos | 0.432469 |
| New Hampshire Avenue | 0.419687 |
| PDQ Virus | 0.451192 |
| complicaciones quizás | 0.416168 |
| Drug Administration | 0.41221 |
| NCI Best Case | 0.435079 |
| datos bibliográficos pubmed | 0.420843 |
| posibles formas | 0.415768 |
| largo plazo | 0.415867 |
| mayorÃa usó células | 0.468567 |
| fase ii | 0.489698 |
| único efecto | 0.414956 |
| National Cancer Institute | 0.423353 |
| siguientes riesgos | 0.413615 |
| cepa mth-68 | 0.496578 |
| distintos factores | 0.416278 |
| Instituto Nacional | 0.505259 |
|
| acupuntura ayuda | 0.4111 |
| células tumorales enteras | 0.475674 |
| Salud Complementaria | 0.443057 |
| sustancias llamadas citocinas | 0.426511 |
| Visuals Online | 0.413937 |
| complementarias revisa | 0.419519 |
| Physician Data Query | 0.480164 |
| cuarto estudio | 0.414722 |
| Estados Unidos | 0.771775 |
| células enteras | 0.494193 |
| libre uso | 0.416835 |
| página manejo | 0.41298 |
| ¿El tratamiento | 0.429077 |
| ¿Los beneficios | 0.412098 |
| juntos cam | 0.411689 |
| suficientes resultados prometedores | 0.425777 |
| células renales | 0.45757 |
| Series Program | 0.411543 |
| medicina complementaria | 0.961806 |
|
CLICK HERE |
| 16644 |
National Cancer Institute |
Html |
es |
Régimen Gonzalez (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso del régimen Gonzalez como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Life Sci | 0.504011 |
| Chabot JA | 0.503454 |
| efectos antineoplásicos directos | 0.502996 |
| enzima pancreática porcina | 0.506836 |
| revisión externa journal | 0.505701 |
| Isenman L | 0.503932 |
| Krebs ET | 0.503536 |
| with gemcitabine-based chemotherapy | 0.507748 |
| Isaacs LL | 0.521605 |
| Clinical Pearls News | 0.516873 |
| enzimas pancreáticas porcinas | 0.512289 |
| estudio clÃnico | 0.503404 |
| Rothman S | 0.503859 |
| Fine RL | 0.5034 |
| William Donald Kelley | 0.502696 |
| Instituto Nacional | 0.515061 |
| enzyme treatment | 0.536871 |
| Aliaga C | 0.503794 |
| Gonzalez NJ | 0.605468 |
| with nutrition | 0.522734 |
| Estados Unidos | 0.511805 |
| mammary tumor metastasis | 0.507989 |
| Moneychanger July | 0.504705 |
| Clinical Oncology Article | 0.50262 |
| Liebow C | 0.503937 |
|
| Gonzalez Regimen | 0.511241 |
| Cancer Coalition | 0.503421 |
| enzimas digestivas intactas | 0.50677 |
| Tsai WY | 0.503533 |
| Nutr Cancer | 0.527006 |
| PDQ Régimen Gonzalez | 0.516804 |
| enzimas pancreáticas otc | 0.512028 |
| National Cancer Institute | 0.503592 |
| treatment with | 0.503692 |
| diet therapy | 0.502711 |
| accessed april | 0.540709 |
| complejo tratamiento | 0.503552 |
| Gonzalez Nicholas | 0.510997 |
| Clin Oncol | 0.503748 |
| Kelley WD | 0.504653 |
| enzimas pancreáticas | 0.789985 |
| régimen gonzalez | 0.975131 |
| suplementos alimentarios otc | 0.504496 |
| tumor mamario murino | 0.502751 |
| Pittman B | 0.503853 |
| torrente circulatorio | 0.504682 |
| Moneychanger interview | 0.504631 |
| Pearls News November | 0.516553 |
| Nicholas Gonzalez | 0.53567 |
|
CLICK HERE |
| 16811 |
National Cancer Institute |
Html |
es |
Cartílago (bovino y de tiburón) (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Shirai E | 0.323137 |
| cancer treatment | 0.318107 |
| relation with cartilage-derived | 0.318214 |
| Langer R | 0.391189 |
| Enomoto M | 0.357345 |
| Prudden JF | 0.438802 |
| Biol Chem | 0.333806 |
| shark cartilage | 0.967013 |
| shark cartilage with | 0.323621 |
| Biol Response Mod | 0.535917 |
| Cartilage-derived growth factor | 0.322107 |
| tumor angiogenesis | 0.329827 |
| cultured endothelial cells | 0.316222 |
| Cancer Res | 0.3293 |
| inhibitor from shark | 0.3338 |
| Natl Cancer Inst | 0.381802 |
| novel shark cartilage | 0.322776 |
| shark cartilage extract | 0.362678 |
| with cartilage-derived anti-tumor | 0.3188 |
| powdered shark cartilage | 0.321655 |
| Japanese shark cartilage | 0.32145 |
| with cartilage-derived | 0.324288 |
| Biophys Res Commun | 0.316215 |
| Biochem Biophys Res | 0.31677 |
| inhibits tumor neovascularization | 0.319919 |
|
| Biol Int Rep | 0.323384 |
| stem cell | 0.318383 |
| potent shark cartilage-derived | 0.318104 |
| Takigawa M | 0.353102 |
| tumor growth | 0.323007 |
| cartilage extract | 0.364849 |
| anti-angiogenic antitumor factor | 0.318413 |
| stem cell assay | 0.317911 |
| Cell Biol Int | 0.327732 |
| its relation with | 0.316418 |
| cell line produces | 0.317193 |
| Exp Med Biol | 0.323654 |
| from cartilage | 0.324423 |
| shark cartilage-derived angiogenesis | 0.320509 |
| New York | 0.316148 |
| antitumor factor | 0.334004 |
| endothelial cell | 0.365475 |
| Cell Biol | 0.339136 |
| cartÃlago bovino | 0.480214 |
| cartilage contains inhibitors | 0.320628 |
| angiogenesis inhibitor from | 0.364307 |
| from shark cartilage | 0.349703 |
| Sudhalter J | 0.330756 |
| from japanese shark | 0.31927 |
|
CLICK HERE |